Myelofibrosis | Niche & Rare Disease Landscape & Forecast | US/EU5 | 2017

Incyte/Novartis’s Jakafi/Jakavi (ruxolitinib) is the first and only drug approved for MF in the United States (2011) and EU5 (2012). While Jakafi/Jakavi offers a therapeutic option for patients with MF, the drug is associated with discontinuation and loss of response (e.g., patients become refractory to treatment). Furthermore, not all patients benefit from Jakafi/Jakavi, nor does the agent address the full array of symptoms (e.g., anemia). Therefore, significant market opportunity remains for safe and tolerable treatments that can effectively manage the full spectrum of symptoms—thereby negating the need for polypharmacy over long periods of time—as well as for treatment options for patients with baseline thrombocytopenia and anemia.Questions Answered:  What are the sizes of the U.S. and EU5 diagnosed prevalent and incident MF populations? What are the distributions of risk level among diagnosed incident and prevalent cases of primary MF? How will novel therapies be positioned in the current treatment algorithm for MF, and which MF patients will be served by these treatment options in 2026? What are the most promising avenues of research and development? What are the key unmet needs and areas of commercial opportunity for MF? Is the MF pipeline expected to address these needs by 2026?Scope:Market covered: United States, France, Germany, Italy, Spain, and the United Kingdom.Primary research: Six country-specific interviews with hematology specialists.Epidemiology: Diagnosed and drug-treated prevalent cases.Emerging therapies: Phase III/PR: 2; Phase II: 14; coverage of select preclinical and Phase I products.Market forecast: Drug-level sales and patient share of key MF therapies in 2026.Key companies:  Incyte, Novartis, Impact Biomedicines, Celgene, Acceleron, Geron, Janssen, PromediorKey drugs: Jakafi/Jakavi, ruxolitinib, pacritinib, fedratinib, luspatercept, imetelstat, PRM-151